Claims
- 1. A compound of the formula ##STR232## wherein: R.sup.1 is hydrogen, or from one to four, the same or different, substituents in any of the 1-,2-, 3- or 4-positions selected from the group consisting of lower-alkoxy, lower-alkyl, halogen, hydroxy, OC(O)alkyl-CH=CH-alkyl, OCO(O)alkyl, OC(O)-lower-alkenyl-C(O)Oalkyl, alkocy, OC(O)alkylC(O)alkyl, hydroxymethyl, nitro, amino and lower-alkylsulfonylamino or R.sup.1 is a fused benzene ring;
- R.sup.2 is hydrogen, lower-alkyl, cyano or lower-alkoxycarbonyl;
- R.sup.3 and R.sup.4 is independently hydrogen, or lower-alkyl; or R.sup.3 and R.sup.4 together form a cycloalkyl ring, or a lower alkylidene group;
- R.sup.5 and R.sup.6 are independently a 5-membered heterocyclic ring system (or said 5-membered heterocyclic ring system substituted on any available carbon atom thereof by hydroxy, lower-alkyl, oxo, nitro, halogen, or lower-alkoxy; or on any available nitrogen atom thereof by lower-alkyl, phenyl-lower-alkyl, trilower-alkylsilyl, lower-alkylphenylsulfonyl, or trilower-alkylsilyl-lower-alkoxy-lower-alkyl);
- or R.sup.3 and R.sup.5, and/or R.sup.4 and R.sup.6 taken together with the carbon atoms to which they are attached form a bicyclic ring system of the formula A: ##STR233## wherein A is a 5-membered heterocyclic ring system and n is one (or said A ring substituted on any available carbon atom thereof by lower-alkoxy, or lower-alkyl);
- R.sup.7 is hydrogen, or from one to four, the same or different, substituents in any of the 7-, 8-,9-, or 10-positions selected from the group consisting of lower-alkyl, lower-alkanolyloxy, halogen, nitro, hydroxy, lower-alkoxy, methylenedioxy, polyfluorolower-alkyl, OCO(CH.sub.2).sub.m C(O)Oalkyl, OC(O)alkyl, C(O)Oalkyl, CO.sub.2.sup.-, carboxy, sulfo, SO.sub.3.sup.-, PO.sub.3 H; PO.sub.3.sup.- cyano, polychlorolower-alkyl, OC(O)alkyl-CH=CH-alkyl, OC(O)-lower-alkenyl-C(O)Oalkyl, alkoxy, OC(O)alkylC(O)Oalkyl, halomethyl, hydroxymethyl, amino and lower-alkylsulfonylamino wherein m is an integer from one to four and/or R.sup.7 is a fused pyrazole ring; alkylsulfonylamino wherein m is an integer from one to four and/or R.sup.7 is a fused pyrazole ring;
- X.sup.- is an anion; and p is zero when R.sup.7 is a negatively charged radical and p is one when R.sup.7 is other than a negatively charged radical; or a pharmaceutically acceptable acid-addition salt of basic members thereof; or a solvate thereof; or a stereoisomer thereof; with the following provisos: a) at least one of R.sup.5 and R.sup.6 when taken individually must be a substituted or unsubstituted 5-membered heterocyclic ring system and b) R.sup.5 and R.sup.6 cannot be furanyl.
- 2. A compound according to claim 1 wherein:
- R.sup.1 is hydrogen, or from one to four, the same or different, substituents in any of the 1-,2-, 3- or 4-positions selected from the group consisting of lower-alkoxy, lower-alkyl and halogen;
- R.sup.2 is hydrogen or lower-alkyl;
- R.sup.3 and R.sup.4 are independently hydrogen, or lower-alkyl; or R.sup.3 and R.sup.4 together form a cycloalkyl ring, or a lower alkylidene group;
- R.sup.5 and R.sup.6 are independently a 5-membered heterocyclic ring system (or said 5-membered heterocyclic ring system substituted on any available carbon atom thereof by lower-alkyl, oxo, nitro, halogen, or lower-alkoxy; or on any available nitrogen atom thereof by lower-alkyl, phenyl-lower-alkyl, trilower-alkylsilyl, or trilower-alkylsilyl-lower-alkoxy-lower-alkyl);
- or R.sup.3 and R.sup.5, and/or R.sup.5 and R.sup.6 taken together with the carbon atoms to which they are attached form a bicyclic ring system of the formula A: ##STR234## wherein A is a 5-membered heterocyclic ring system and n is one (or said A ring substituted on any available carbon atom thereof by lower-alkoxy, or lower-alkyl);
- R.sup.7 is hydrogen, or from one to four, the same or different, substituents in any of the 7-, 8-,9-, or 10-positions selected from the group consisting of lower-alkyl, lower-alkanolyloxy, halogen, nitro, hydroxy, lower-alkoxy, methylenedioxy, polyfluorolower-alkyl, OCO(CH.sub.2).sub.m C(O)Oalkyl, OC(O)alkyl, C(O)Oalkyl, CO.sub.2.sup.-, carboxy, sulfo, SO.sub.3.sup.-, PO.sub.3 H; PO.sub.3.sup.- cyano, polychlorolower-alkyl, wherein m is an integer from one to four;
- X.sup.- is an anion; and p is zero when R.sup.7 is a negatively charged radical and p is one when R.sup.7 is other than a negatively charged radical; or a pharmaceutically acceptable acid-addition salt of basic members thereof; or a solvate thereof; or a stereoisomer thereof; with the following provisos: a) at least one of R.sup.5 and R.sup.6 when taken individually must be a substituted or unsubstituted 5-membered heterocyclic ring system and b) R.sup.5 and R.sup.6 cannot be furanyl.
- 3. A compound according to claim 2 wherein R.sup.5 and R.sup.6 are independently a 5-membered heterocyclic ring system (or said 5-membered heterocyclic ring system substituted on any available carbon atom thereof by lower-alkyl, oxo, or lower-alkoxy; or on any available nitrogen atom thereof by lower-alkyl, phenyl-lower-alkyl, trilower-alkylsilyl, or trilower-alkylsilyl-lower-alkoxy-lower-alkyl); and R.sup.7 is hydrogen, or from one to four, the same or different, substituents in any of the 7-,8-,9- or 10-membered positions selected from the group consisting of lower-alkyl, lower-alkanoyloxy, halogen, nitro, hydroxy, lower-alkoxy, methylenedroxy, polyfluorolower-alkyl, SO.sub.3 -, and polychlorolower-alkyl.
- 4. A compound according to claim 2 wherein R.sup.5 and R.sup.6 are independently a 5-membered heterocyclic ring system (or said 5-membered heterocyclic ring system substituted on any available carbon atom thereof by lower-alkyl, oxo, or lower-alkoxy; or on any available nitrogen atom thereof by lower-alkoxyphenyl-lower-alkyl, trilower-alkylsilyl, or trilower-alkylsilyl-lower-alkoxy-lower-alkyl), and wherein A is a 5-membered heterocyclic ring system and n is one (or said A ring substituted on any available carbon atom thereof by lower-alkoxy, or lower-alkyl).
- 5. A compound according to claim 4 wherein R.sup.1 is hydrogen, or one lower-alkyl substituent in any of the 1-,2-,3- or 4-positions; and R.sup.7 is hydrogen, or from one to two, the same or different, substituents in any of the 7-,8-,9- or 10-positions selected from the group consisting of halogen, hydroxy, lower-alkoxy SO.sub.3.sup.- and polyfluorolower-alkyl.
- 6. A compound according to claim 5 wherein R.sup.5 and R.sup.6 are independently a 5-membered heterocyclic ring system selected from the group consisting of thienyl, oxazolyl, thiazolyl, pyrazolyl, triazolyl and pyrrolyl (or said 5-membered heterocyclic ring system substituted on any available carbon atom thereof by lower-alkyl, oxo, or lower-alkoxy; or any available nitrogen atom thereof by lower-alkoxyphenyl-lower-alkyl, trilower-alkylsilyl, or tri-lower-alkylsilyl-lower-alkoxy-lower-alkyl); and
- A is a 5-membered heterocyclic ring system selected form the group consisting of isoxazolyl and thienyl (or said A ring substituted on any available carbon atom thereof by lower-alkoxy, or lower-alkyl).
- 7. A compound according to claim 6 wherein R.sup.5 and R.sup.6 are independently a 5-membered heterocyclic ring system selected from the group consisting of 2-thienyl, 3-thienyl, 4-oxazolyl, 2-thiazolyl, 5-thiazolyl, 5-pyrazolyl, 5-(1,2,3-triazolyl) and 3-pyrrolyl (or said 5-membered heterocyclic ring system substituted on any available carbon atom thereof by methyl, oxo, or methoxy; or any available nitrogen atom thereof by methoxyphenylmethyl, triisopropylsilyl, or (CH.sub.3).sub.3 Si(CH.sub.2).sub.2 OCH.sub.2), ethoxy or ethynyl and A is a 5-membered heterocyclic ring system selected from the group consisting of isoxazolyl and thienyl (or said A ring substituted on any available carbon atom thereof by methoxy, or methyl).
- 8. A compound according to claim 7 wherein R.sup.1 is hydrogen or 1-lower-alkyl; and R.sup.7 is hydrogen, or from one to two, the same or different, substituents in any of the 7-,8-,9- or 10-positions selected from the group consisting of bromine, fluorine, hydroxy, methoxy, isopropyoxy, SO.sub.3.sup.- and trifluoromethyl.
- 9. A compound according to claim 8 wherein R.sup.1 is hydrogen or 1-methyl; and R.sup.2 is hydrogen, methyl, or butyl; and R.sup.3 and R.sup.4 are independently hydrogen, or methyl; or R.sup.3 and R.sup.4 together form a cyclopropyl ring, or a methylidene group.
- 10. A compound according to claim 9 selected from the group consisting of:
- 6,11-ethano-6-methyl-12,12-di(2-thienyl)-6,11-dihydrobenzo[b]quinolizinium X.sup.- ;
- 6,11-ethano-12,12-di(2-thienyl)-6,11-dihydrobenzo[b]quinolizinium X.sup.- ; and
- 6,11-ethano-12,12-di(3-thienyl)-6,11-dihydrobenzo[b]quinolizinium X.sup.-.
- 11. A compound according to claim 10 selected from the group consisting of:
- 6,11-ethano-6-methyl-12,12-di(2-thienyl)-6,11-dihydrobenzo[b]quinolizinium chloride;
- 6,11-ethano-12,12-di(2-thienyl)-6,11-dihydrobenzo[b]quinolizinium chloride; and
- 6,11-ethano-12,12-di(3-thienyl)-6,11-dihydrobenzo[b]quinolizinium chloride.
- 12. A compound according to claim 9 which is selected from the group consisting of:
- 6,11-ethano-12,12-di(3-pyrrolyl)-6,11-dihydrobenzo[b]quinolizinium chloride.
- 13. A compound according to claim 2 wherein R.sup.5 and R.sup.6 are independently a 5-membered heterocyclic ring system selected from the group consisting of pyrazolyl, triazolyl, imidazolyl and pyrrolyl (or said 5-membered heterocyclic ring system substituted on any available carbon atom thereof by lower-alkoxy; or any available nitrogen atom thereof by lowre-alkyl, lower-alkoxyphenyllower-alkyl, or trilower-alkylsilyl; R.sup.1 is hydrogen or one or lower-alkoxy or halogen substituent in any of the 1-,2-, 3- or 4-positions; and R.sup.7 is hydrogen, or from one to two, the same or different, substituents in any of the 7-, 8-, 9- or 10- positions selected from the group consisting of OC(O)alkyl, OC(O)(CH.sub.2).sub.m C(O)Oalkyl, hydroxy, lower-alkoxy, methylenedioxy, halogen and nitro.
- 14. A compound according to claim 13 wherein R.sup.5 and R.sup.6 are independently a 5-membered heterocyclic ring system selected from the group consisting of 3-, 4- and 5-pyrazolyl, 5-(1,2,4-triazolyl), 2-imidazolyl and 3-pyrrolyl (or said 5-membered heterocyclic ring system substituted on any available carbon atom thereof by methoxy, or on any available nitrogen atom thereof by methyl, methoxyphenylmethyl, or triisopropylsilyl); R.sup.1 is hydrogen, 1-halogen, or 1-lower-alkoxy; and R.sup.7 is hydrogen, or from one to two, the same or different, substituents in any of the 7-, 8-, 9- or 10- positions selected from the group consisting of OC(O)(CH.sub.2).sub.6 CH.sub.3, OCO(CH.sub.2).sub.2 C(O)OCH.sub.2 CH.sub.3, OC(O)CH.sub.3, OC(O)t-Bu, hydroxy, methoxy, methylenedioxy, chloro, fluoro and nitro.
- 15. A compound according to claim 14 wherein R.sup.1 is hydrogen, 1-fluoro, or 1-methoxy; R.sup.2 is hydrogen, or methyl; and R.sup.3 and R.sup.4 are independently hydrogen or methyl; or R.sup.3 and R.sup.4 together form a methylidene group.
- 16. 6,11-Ethano-12,12-di(3-pyrazolyl)-9-hydroxy-6,11-dihydrobenzo[b]quinoliziniuim chloride according to claim 15.
- 17. A compound according to claim 1 wherein R.sup.1 is from one to four, the same or different, substituents in any of the 1-, 2-, 3- or 4-positions selected from the group consisting of hydroxy, OC(O)alkyl-CH=CH-alkyl, OC(O) alkyl, OC(O)-lower-alkenyl-C(O)Oalkyl, alkoxy, OC(O)alkylC(O)Oalkyl, hydroxymethyl, nitro, amino and lower-alkylsulfonylamino; or R.sup.1 is a fused benzene ring.
- 18. A compound according to claim 17 wherein:
- R.sup.1 is one substituent in any of the 1-, 2-, 3-, or 4- positions selected from the group consisting of hydroxy, and OC(O)alkyl; or R.sup.1 is a fused benzene ring;
- R.sup.2, R.sup.3, R.sup.4 and R.sup.7 are hydrogen; and
- R.sup.5 and R.sup.6 are independently a 5-membered heterocyclic ring system selected from the group consisting of thienyl, oxazolyl, thiazolyl, pyrazolyl, triazolyl, pyrrolyl and imidazolyl.
- 19. A compound according to claim 18 wherein R.sup.1 is 1-hydroxy, 1-OC(O)CH.sub.3 or a fused benzene ring.
- 20. A compound according to claim 1 wherein R.sup.2 is cyano or lower alkoxycarbonyl.
- 21. A compound according to claim 20 wherein: R.sup.1, R.sup.3, R.sup.4 and R.sup.7 are hydrogen; and R.sup.5 and R.sup.6 are independently selected from the group consisting of thienyl, oxazolyl, thiazolyl, pyrazolyl, triazolyl, pyrrolyl and imidazolyl.
- 22. A compound according to claim 1 wherein R.sup.7 is from one to four, the same or different, substituents in any of the 7-, 8-, 9- or 10-positions selected from the group consisting of OC(O)alkyl-CH.dbd.CH-alkyl, OC(O)-lower-alkenyl-C(O)Oalkyl, alkoxy, OC(O)alkylC(O)Oalkyl, halomethyl, hydroxymethyl, amino and lower-alkylsulfonylamino and/or R.sup.7 is a fused pyrazole ring.
- 23. A compound according to claim 22 wherein: R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are hydrogen; and R.sup.5 and R.sup.6 are independently a 5-membered heterocyclic ring system selected from the group consisting of thienyl, oxazolyl, thiazolyl, pyrazolyl, triazolyl, pyrrolyl and imidazolyl.
- 24. A compound according to claim 23 wherein R.sup.7 is one substituent selected from the group consisting of OC(O)(CH.sub.2).sub.7 HC=CH-(CH.sub.2).sub.7 CH.sub.3, OC(O)-CH=CH-C(O)OCH.sub.2 CH.sub.3, O(CH.sub.2).sub.7 CH.sub.3, OC(O)C(CH.sub.3)2CH.sub.2 C(O)OCH.sub.2 CH.sub.3, chloromethyl, hydroxymethyl, and OC(O)C(CH.sub.3).sub.2 CH.sub.2 C(O)O(CH.sub.2).sub.7 CH.sub.3 ; and/or R.sup.7 is a fused pyrazole ring.
- 25. A pharmaceutical composition which comprises a compound of the formula: ##STR235## wherein: R.sup.1 is hydrogen, or from one to four, the same or different, substituents in any of the 1-,2-, 3- or 4- positions selected from the group consisting of lower-alkoxy, lower-alkyl, halogen, hydroxy, OC(O)alkyl-CH=CH-alkyl, OC(O)alkyl, OC(O)-lower-alkenyl-C(O)Oalkyl, alkoxy, OC(O)alkylC(O)Oalkyl, hydroxymethyl, nitro, amino and lower-alkylsulfonylamino or R.sup.1 is a fused benzene ring;
- R.sup.2 is hydrogen, lower-alkyl, cyano or lower-alkoxycarbonyl;
- R.sup.3 and R.sup.4 are independently hydrogen, or lower-alkyl; or R.sup.3 and R.sup.4 together form a cycloalkyl ring, or a lower alkylidene group;
- R.sup.5 and R.sup.6 are independently a 5-membered heterocyclic ring system or said 5-membered heterocyclic ring system substituted on any available carbon atom thereof by hydroxy, lower-alkyl, oxo, nitro, halogen, or lower-alkoxy; or on any available nitrogen atom thereof by loweralkyl, phenyl-lower-alkyl trilower-alkylsilyl, lower-alkylphenylsulfonyl, or trilower-alkylsilyl-lower-alkoxy-lower-alkyl;
- or R.sup.3 and R.sup.5, and/or R.sup.4 and R.sup.6 taken together with the cabon atoms to which they are attached form a bicyclic ring system of the formula A: ##STR236## wherein A is a 5-membered heterocyclic ring system and n is one (or said A ring substituted on any available carbon atom thereof by lower-alkoxy, or lower-alkyl);
- R.sup.7 is hydrogen, or from one to four, the same or different, substituents in any of the 7-, 8-,9-, or 10- positions selected from the group consisting of lower-alkyl, lower-alkanoyloxy, halogen, nitro, hydroxy, lower-alkoxy, methylenedioxy, polyfluorolower-alkyl, OCO(CH.sub.2).sub.m C(O)Oalkyl, OC(O)alkyl, C(O)Oalkyl, CO.sub.2.sup.-, carboxy, sulfo, SO.sub.3.sup.-, PO.sub.3 H; PO.sub.3.sup.- cyano, polychlorolower-alkyl, OC(O)alkyl-CH=CH-alkyl, OC(O)-lower-alkenyl-C(O)Oalkyl, alkoxy, OC(O)alkylC(O)Oalkyl, halomethyl, hydroxymethyl, amino and lower-alkylsulfonylamino wherein m is an integer from one to four and/or R.sup.7 is a fused pyrazole ring;
- X.sup.- is an anion; and p is zero when R.sup.7 is a negatively charged radical and p is one when R.sup.7 is other than a negatively charged radical; or a pharmaceutically acceptable acid-addition salt of basic members thereof; or a solvate thereof; or a stereoisomer thereof; together with a pharmaceutically acceptable carrier, adjuvant, diluent or vehicle, with the proviso that at least one of R.sup.5 and R.sup.6 when taken individually must be a substituted or unsubstituted 5-membered heterocyclic ring system and R.sup.5 and R.sup.6 cannot be furanyl.
- 26. A method for the treatment or prevention of neurotoxic injuries which comprises administering to a patient in need of such treatment an effective amount of a compound of the formula: ##STR237## wherein: R.sup.1 is hydrogen, or from one to four, the same or different, substituents in any of the 1-,2-, 3- or 4- positions selected from the group consisting of lower-alkoxy, lower-alkyl, halogen, hydroxy, OC(O)alkyl-CH=CH-alkyl, OC(O)alkyl, OC(O)-lower-alkenyl-C(O)Oalkyl, alkoxy, OC(O)alkylC(O)Oalkyl, hydroxymethyl, nitro, amino and lower-alkylsulfonylamino or R.sup.1 is a fused benzene ring;
- R.sup.2 is hydrogen, lower-alkyl, cyano or lower-alkoxycarbonyl;
- R.sup.3 and R.sup.4 are independently hydrogen, or lower-alkyl; or R.sup.3 and R.sup.4 together form a cycloalkyl ring, or a lower alkylidene group;
- R.sup.5 and R.sup.6 are independently a 5- membered heterocyclic ring system or said 5-membered heterocyclic ring system substituted on any available carbon atom thereof by hydroxy, lower-alkyl, oxo, nitro, halogen, or lower-alkoxy; or on any available nitrogen atom thereof by lower-alkyl, phenyl-lower-alkyl, trilower-alkylsilyl, lower-alkylphenylsulfonyl, or trilower-alkylsilyl-lower-alkoxy-lower-alkyl;
- or R.sup.3 and R.sup.5, and/or R.sup.4 and R.sup.6 taken together with the carbon atoms to which they are attached form a bicyclic ring system of the formula A: ##STR238## wherein A is a 5-membered heterocyclic ring system and n is one (or said A ring substituted on any available carbon atom thereof by lower-alkoxy, or lower-alkyl);
- R.sup.7 is hydrogen, or from one to four, the same or different, substituents in any of the 7-, 8-,9-, or 10-positions selected from the group consisting of lower-alkyl, lower-alkanoyloxy, halogen, nitro, hydroxy, lower-alkoxy, methylenedioxy, polyfluorolower-alkyl, OCO(CH.sub.2).sub.m C(O)Oalkyl, OC(O)alkyl, C(O)Oalkyl, CO.sub.2.sup.-, carboxy, sulfo, SO.sub.3.sup.-, PO.sub.3 H; PO.sub.3.sup.- cyano, polychlorolower-alkyl, OC(O)alkyl-CH=CH-alkyl, OC(O)-lower-alkenyl-C(O)Oalkyl, alkoxy, OC(O)alkylC(O)Oalkyl, halomethyl, hydroxymethyl, amino and lower-alkylsulfonylamino wherein m is an integer from one to four and/or R.sup.7 is a fused pyrazole ring;
- X.sup.- is an anion; and p is zero when R.sup.7 is a negatively charged radical and p is one when R.sup.7 is other than a negatively charged radical; or a pharmaceutically acceptable acid-addition salt of basic members thereof; or a solvate thereof; or a stereoisomer thereof; together with a pharmaceutically acceptable carrier, adjuvant, diluent or vehicle, with the proviso that at least one of R.sup.5 and R.sup.6 when taken individually must be a substituted or unsubstituted 5-membered heterocyclic ring system and R.sup.5 and R.sup.6 cannot be furanyl.
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a division of Ser. No. 08/283,317, filed on Jul. 7, 1994, U.S. Pat. No. 5,554,620, which in turn is a continuation-in-part of our prior application Ser. No. 08/121,127, filed Sep. 14, 1993, abandoned.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4888347 |
Woodruff |
Dec 1989 |
|
Non-Patent Literature Citations (2)
Entry |
Cotman CW and Iversen L.L. (1987). TINS 10(7) 263-272. |
Choi DW 1988) Neuron 1, 623-634. |
Divisions (1)
|
Number |
Date |
Country |
Parent |
283317 |
Jul 1994 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
121127 |
Sep 1993 |
|